The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
2 reports, 1 independent
Updated Sep 12
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Novartis
Swiss-American multinational pharmaceutical corporation
Related events
- Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.
- Amgen Inc. trades on the NASDAQ stock exchange.
- Novartis's trial setbacks are negatively affecting market sentiment and causing a stock decline.
- Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
- Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.